FDA-approved drugs can extend lives of cardiac amyloidosis patients

(WISH) — Cardiac amyloidosis is a systemic disorder that affects the heart and can also affect other organs such as the kidneys and nervous system.

AdventHealth says from 50,000-150,000 people in the U.S. have systemic amyloidosis. Patients are being identified earlier than ever, and new drugs approved by the U.S. Food and Drug Administration are prolonging their lives significantly.